Dermatology PAs unpack 4 frightening skin care myths and trends, from sunscreen misinformation and citrus DIYs to overusing actives and beef tallow.
|Articles|June 20, 2023
Study Outlines Common Skin Conditions Among Refugees
Author(s)Lauren Buchanan, MA, Managing Editor
On this World Refugee Day, we delve into a study published this year outlining skin conditions among more than 500 refugees resettling in the United States.
Advertisement
References
1. Fact sheet: U.S. refugee resettlement. National Immigration Forum. February 14, 2022. Accessed June 20, 2023.
2. Ching AH, Tay T, Brown B, Mohareb AM, Sethi A, Annamalai A. Dermatologic conditions of adult refugees following resettlement in the United States, 2015 to 2018. J Migr Health. 2023;7:100183. Published 2023 Mar 21. doi:10.1016/j.jmh.2023.100183
Advertisement
Related to this article
The approval expands the IL-23 inhibitor’s indications beyond moderate-to-severe plaque psoriasis to include adults with active psoriatic arthritis.
Find out what skin care products and aesthetic innovations clinicians are recommending to patients for the month of October.
Clinician FAQ on remibrutinib's FDA approval in symptomatic dermographism: RemIND efficacy, mechanism, safety, and supporting CSU evidence.
Elevate-Derm Summer 2026 faculty share practical lessons on hair loss exams, PIH, geriatric dermatology, and managing cholesterol rises on JAK inhibitors.
Atopic dermatitis care is evolving with flexible biologic dosing, expanded pediatric options, and novel oral, topical, and systemic therapies.
Updated SKYRIZI labeling allows clinicians to use clinical judgment when determining the need for TB evaluation before treatment.
Experts outline how to recognize undertreated psoriasis, assess incomplete response, and make individualized decisions when escalating therapy.
Advertisement
Advertisement
Trending on Dermatology Times
1
FDA Approves Tildrakizumab for Active Psoriatic Arthritis
2
Beyond Dry Skin: Rethinking Common Eczema Misconceptions
3
FAQ: Remibrutinib (Rhapsido) Becomes First FDA-Approved Treatment for a Chronic Inducible Urticaria
4
How Approvals, Setbacks, and a Crowded Pipeline Are Reshaping the AD Treatment Landscape
5